← Back
Data updated: Jun 28, 2026
LANTHEUS MEDCL
Specialty Pharmaceuticals
LANTHEUS MEDCL is a specialty pharmaceutical company with 6 FDA-approved products.
1974
Since
6
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules
Upcoming FDA Decisions
Full Calendar → Aug 13, 2026 — LNTH
LANTHEUS MEDCL's Key Drugs
LANTHEUS MEDCL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
LANTHEUS MEDCL's Recent FDA Approvals
New NDA/BLA approvals for LANTHEUS MEDCL over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
LANTHEUS MEDCL's Therapeutic Areas
Disease areas where LANTHEUS MEDCL has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
LANTHEUS MEDCL Pipeline Snapshot
Active clinical trials for LANTHEUS MEDCL across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1974-10-11
- Latest
- 2024-03-01
- Applications
- 5